Targeted combination immunotherapy
AssigneeImmunomedics, Inc.
InventorsGary L. Griffiths, Hans J. Hansen, David M. Goldenberg
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods for treating cancer wherein more than one therapeutic agent is used, with each of the therapeutic agents having different tumor-killing capabilities, and wherein the therapeutic agents are delivered to the tumor sites using combined targeting and pre-targeting methods. The methods of the present invention achieve good tumor to non-tumor ratios of the therapeutic agents, and are effective for cancer therapy.
Claims45
A composition for effecting therapy of a tumor or an infectious disease in a patient, comprising:
- (A) a first conjugate comprising a targeting moiety and a first therapeutic agent, wherein the targeting moiety selectively binds to a marker substance produced by or associated with the tumor or infectious disease causing agent and to a low molecular weight hapten;
- (B) optionally, a clearing agent;
- and
- (C) a second conjugate comprising a low molecular weight hapten to which said first conjugate binds and a second therapeutic agent, wherein the second therapeutic agent is the same as or different from the first therapeutic agent.
A composition for effecting therapy of a tumor or an infectious disease in a patient, comprising:
- (A) a first conjugate comprising a targeting moiety, a first member of a binding pair, and a first therapeutic agent, wherein the targeting moiety selectively binds to a marker substance produced by or associated with the tumor or with the infectious disease causing agent;
- (B) optionally, a clearing agent;
- and
- (C) a second conjugate comprising a complementary member of said binding pair and a second therapeutic agent, wherein the second therapeutic agent is the same as or different from the first therapeutic agent and is selected from the group consisting of a drug-polymer conjugate, a PEG-drug conjugate and a drug-liposome conjugate.
A composition for effecting therapy of a tumor or an infectious disease in a patient, comprising:
- (A) a first conjugate comprising a targeting moiety and a first therapeutic agent, wherein the targeting moiety is multivalent and selectively binds to multiple epitopes of a marker substance produced by or associated with the tumor or infectious disease causing agent or binds to multiple marker substances produced by or associated With the tumor or infectious disease causing agent,
- (B) optionally, a clearing agent;
- and
- (C) a second conjugate comprising a complementary member of said binding pair and a second therapeutic agent, wherein the second therapeutic agent is the same as or different from the first therapeutic agent,
- wherein the binding pair is selected from the group consisting of (a) complementary DNA fragments, (b) complementary peptide oligonucleotides, and (c) corresponding enzymes and prodrug substrates.
Dependencies are inferred from the claim text.